Clinical Trial Update: HALOS: A Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of Multiple Ascending Doses of ION582 in Participants With Angelman Syndrome [Phase 1, Phase 2]

View source ↗

Summary

This document describes a Phase 1/2 clinical trial evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of IO…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Angelman Syndrome

Drugs mentioned

• ION582

Snippet

Sponsor: Ionis Pharmaceuticals, Inc. | Conditions: Angelman Syndrome | Phase 1, Phase 2 | Status: RECRUITING